Ítem
Acceso Abierto

Prevalencia del déficit de vitamina D y su relación con la expresión clínica de la Esclerosis Múltiple y Neuromielitis óptica en Bogotá
dc.contributor.advisor | Velez-van-Meerbeke, Alberto | |
dc.contributor.advisor | Bareño Silva, José | |
dc.creator | Ortíz Salas, Paola | |
dc.creator.degree | Magíster en epidemiología | |
dc.date.accessioned | 2017-10-25T12:28:33Z | |
dc.date.available | 2017-10-25T12:28:33Z | |
dc.date.created | 2017-09-14 | |
dc.date.issued | 2017 | |
dc.description | Introducción: La hipovitaminosis D es un reciente factor de riesgo en Esclerosis Múltiple, Neuromielitis óptica y espectro de Neuromielitis óptica, dado que se ha relacionado con desarrollo y progresión de estas enfermedades. El objetivo es determinar la prevalencia del déficit de vitamina D en pacientes con esclerosis múltiple y neuromielitis óptica y su relación con la expresión clínica. Materiales y Métodos Estudio de Prevalencia analítica donde se tomaron todos los pacientes mayores de 18 años con diagnóstico de Esclerosis Múltiple por criterios de Mcdonald, Neuromielitis óptica y espectro de Neuromielitis óptica que asisten a 3 centros de hospitalización y/o consulta de neurología de Bogotá, entre de enero de 2014 a diciembre 2016. Resultado: El 71% de los pacientes con estas enfermedades tienen déficit de vitamina D, con 26.8 ± 6.1 ng/ml. No se encontró diferencia significativa entre la hipovitaminosis y tiempo (años) con la enfermedad desmielinizante (p=0.55) ni con la severidad de la enfermedad determinada por puntaje de discapacidad según EDSS (p=0.34). Tampoco se encontró factores que influyeran sobre la prevalencia de la hipovitaminosis (tiempo de exposición, uso de bloqueador solar, tipo de piel). Conclusión: Pacientes con esclerosis múltiple y neuromielitis óptica de Bogotá tienen déficit de vitamina D, sin embargo, no encontramos relación con las variables clínicas de la enfermedad. | spa |
dc.description.abstract | Introduction: The hypovitaminosis D is a recent risk factor in multiple sclerosis, optic neuromyelitis and spectrum of optic neuromyelitis, since it has been associated with the development and progression of these diseases. The objective to determine the prevalence of vitamin D deficiency in multiple sclerosis and optic neuromyelitis and its relationship with the clinical. Materials and Methods: Observational cross-sectional study, in which all patients older than 18 years with a diagnosis of Multiple Sclerosis with crteria of Mcdonald, optic neuromyelitis and optic neuromyelitis spectrum were enrolled, attending 3 centers of hospitalization and/or neurology consultation in Bogotá, between January 2014 to December 2016. Outcome: It was found that 71% of patients with these diseases had vitamin D deficiency, with 26. 8 ± 6. 1 ng / ml. No significant difference was found between hypovitaminosis and time (years) with demyelinating disease (p = 0. 55) or disease severity as determined by EDSS score (p = 0. 34), as well as factors that may influence its Prevalence (time of exposure, sunscreen and skin type). Conclusion: Patients with multiple sclerosis and optic neuromyelitis in Bogotá have vitamin D deficits, however, we did not find any relation with the clinical variables of the disease. | eng |
dc.format.mimetype | application/pdf | |
dc.identifier.doi | https://doi.org/10.48713/10336_13831 | |
dc.identifier.uri | http://repository.urosario.edu.co/handle/10336/13831 | |
dc.language.iso | spa | |
dc.publisher | Universidad del Rosario | spa |
dc.publisher.department | Facultad de medicina | spa |
dc.publisher.program | Maestría en Epidemiología | spa |
dc.rights.accesRights | info:eu-repo/semantics/openAccess | |
dc.rights.acceso | Abierto (Texto completo) | spa |
dc.rights.cc | Atribución-NoComercial-SinDerivadas 2.5 Colombia | spa |
dc.rights.cc | Atribución-NoComercial-SinDerivadas 2.5 Colombia | spa |
dc.rights.cc | Atribución-NoComercial-SinDerivadas 2.5 Colombia | spa |
dc.rights.licencia | EL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos. | spa |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | |
dc.source.bibliographicCitation | Alharbi FM. Update in vitamin D and multiple sclerosis. Neurosciences (Riyadh). 2015;20(4):329-35. | |
dc.source.bibliographicCitation | Amezcua L, Chung RH, Conti DV, Langer-Gould AM. Vitamin D levels in Hispanics with multiple sclerosis. J Neurol. 2012;259(12):2565-70. | |
dc.source.bibliographicCitation | Tuzun E, Kucukhuseyin O, Kurtuncu M, Turkoglu R, Yaylim I. Reduced serum vitamin D levels in neuromyelitis optica. Neurol Sci. 2015;36(9):1701-2 | |
dc.source.bibliographicCitation | Papais-AlvarengaRM V, CarraA,CastilloISd,FlorentinS,DiazdeBedoya FH, et al. CentralNervousSystemIdiopathic InflammatoryDemyelinatingDisordersin SouthAmericans:ADescriptive,Multicenter, Cross-SectionalStudy. PLoSONE. 2015;10(7):e0127757 | |
dc.source.bibliographicCitation | Wingerchuk DM BB, Bennett JL, Cabre P, Carroll W, et al. . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;14(85):177-89 | |
dc.source.bibliographicCitation | Holick MF SQ, Liu WW, Chen TC. . The vitamin D content of fortified milk and infant formula. N Engl J Med 1992;327:1637-42 | |
dc.source.bibliographicCitation | Favus EMJ. Vitamin D: Photobiology, metabolism, mechanism of action, and clinical applications In: Primer on the of minerol metabolism third edition. Philadelphia. New York.: Lippincott. Raver | |
dc.source.bibliographicCitation | Reichel H. KH, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med 1889;320::981-91 | |
dc.source.bibliographicCitation | Chen TC CF, Lu Z, Mathieu J, Person KS, Zhang A, Kohn N, Martinello S, Berkowitz R, Holick MF. Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys. 2007;15(460(2)):213-7. | |
dc.source.bibliographicCitation | Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol. 2010;9(6):599-612 | |
dc.source.bibliographicCitation | Tian XQ CT, Matsuoka LY, et al. Kinectic and thermodinamic studies of the conversion of previtamin D3 in human skin. J Biol Chem 1993;268:14888-92 | |
dc.source.bibliographicCitation | Tian XQ CT, Lu Z, et al. . Characterization of the translocation process of vitamin D3 from the skin into the circulation. Endocrinology. 1994;135:655-61 | |
dc.source.bibliographicCitation | MF H. The Cutaneous Photosynthesis of Previtamin D3: A Unique Photoendocrine system. . J Invest Dermatol 1981;76:51-8 | |
dc.source.bibliographicCitation | Malvy DJ1 GC, Preziosi P, Galan P, Chapuy MC, Maamer M, Arnaud S, Meunier PJ, Hercberg S, Tschachler E. Relationship between vitamin D status and skin phototype in general adult population. Photochem Photobiol. 2000;71(4):466-9. | |
dc.source.bibliographicCitation | Clemens TL HS, Adams JS, et al. . Increased skin pigment reduces the capacity of skin to synthesize vitamin D3. . Lancet 1982:1:74-6 | |
dc.source.bibliographicCitation | Matsuoka LY IL, Worstman J., et al. Sunscreen suppresscutaneous vitamin D3 synthesis. . J Clin Endocrinol Metab 1987(64):1165-8 | |
dc.source.bibliographicCitation | Need H. MA, Horowitz H., et al. Effects of skin thickness age, body fat, and sunlight on serum 25-hydroxyvitamin D. Am J Clin Nutr 1993;58::882-5. | |
dc.source.bibliographicCitation | MacLaughlin J. HM. Again decreases the capacity of human skin to produce vitamin D3. . J Clin Invest 1985;76:1536-8 | |
dc.source.bibliographicCitation | MF. H. Vitamin D: New horizons for the 21st centyry. . Am J Clin Nutr 1994;;60:619- 30 | |
dc.source.bibliographicCitation | Ohyma Y. NMEGea. Structural characterization of the gene encoding rat 25-hydroxyvitamin D3 24-hydroxylase. . Biochemistry 1993;32:76-82 | |
dc.source.bibliographicCitation | WL. M. Genetics of vitamin D biosynthesis and its disorders. Best Practice & Research Clinical Endocrinology and Metabolism. 2001;15 95-109 | |
dc.source.bibliographicCitation | Ohyma Y. NM, Okuda K. . Cloning and expression of cDNA encording 25-hydroxyvitamin D3 24-hydroxylase. FEBS Letters 1991;278:195-8. | |
dc.source.bibliographicCitation | Porojnicu AC LZ, Robsahm TE, Berg JP, Dahlback A, Moan J. . Changes in risk of death from breast cancer with season and latitude: sun exposure and breast cancer survival in Norway. Breast Cancer Res Treat 2007;102(3):323-8 | |
dc.source.bibliographicCitation | Guinot C MD, Preziosi P, Galan P, Chapuy M, Maamer M, et al. . Vitamin D concentrations in blood and skin phototype in a general adult population in France. Ann Dermatol Venereol 2000;127(12):1073-6 | |
dc.source.bibliographicCitation | Mokry LE, Ross S, Ahmad OS, Forgetta V, Smith GD, Leong A, et al. Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLoS Med. 2015;12(8):e1001866 | |
dc.source.bibliographicCitation | Mandia D FO, Nosari G, Montomoli C, Zardini E, et al. Environmental Factors and Multiple Sclerosis Severity: A Descriptive Study Int J Environ Res Public Health. 2014;11:6417-32 | |
dc.source.bibliographicCitation | A. A. Environmental factors in multiple sclerosis. Expert Rev Neurother. 2013;13(12s):3-9. | |
dc.source.bibliographicCitation | Eskandari G GM, Yekaninejad MS, Sahraian MA, Gorji R, et al. Iran J Neurol 2015 Comparison of serum vitamin D level in multiple sclerosis patients, their siblings, and healthy controls 2015;14(2):81-5 | |
dc.source.bibliographicCitation | Min JH, Waters P, Vincent A, Cho HJ, Joo BE, Woo SY, et al. Low levels of vitamin D in neuromyelitis optica spectrum disorder: association with disease disability. PLoS One. 2014;9(9):e107274 | |
dc.source.bibliographicCitation | James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV. The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler. 2013;19(12):1571-9 | |
dc.source.bibliographicCitation | Fitzgerald KC, Munger KL, Kochert K, Arnason BG, Comi G, Cook S, et al. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurol. 2015:1-8 | |
dc.source.bibliographicCitation | Trang HM, Cole DE, Rubin LA, et al. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998; 68: 854–858 | |
dc.source.bibliographicCitation | Armas LA, Hollis BW and Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89: 5387–5391 | |
dc.source.bibliographicCitation | Shayganeejad V, Janghorbani M, Ashtari F, et al. Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo controlled trial. Multiple Sclerosis International 2012; 2012: doi:10.1155/2012/452541 | |
dc.source.bibliographicCitation | Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-esca¬lation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010; 74: 1852–1859 | |
dc.source.bibliographicCitation | Fragoso YD, Adoni T, Alves-Leon SV, Apostolos-Pereira SL, Arruda WO, et al. No correlation was observed between vitamin D levels and disability of patients with multiple sclerosis between latitudes 18° and 30° South. Arq Neuropsiquiatr. 2017 Jan;75(1):3-8 | |
dc.source.bibliographicCitation | Becker J, Callegaro D, Lana-Peixoto MA, Talim N, Vidaletti T, de Paula Corrêa M5. Hypovitaminosis D association with disease activity in relapsing remitting multiple sclerosis in Brazil. J Neurol Sci. 2016 Apr 15;363:236-9. | |
dc.source.bibliographicCitation | E. Thouvenot, M. Orsini, J.P. Daures,W. Camu. Vitamin D is associatedwith degree of disability in patients with fully ambulatory relapsing–remitting multiple sclerosis. Eur. J. Neurol. 22 (3) (2015) 564–569 | |
dc.source.bibliographicCitation | A. Ascherio, K.L. Munger, R. White, K. Köchert, K.C. Simon, C.H. Polman, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression, JAMA Neurol. 71 (3) (2014) 306–314. | |
dc.source.instname | instname:Universidad del Rosario | spa |
dc.source.reponame | reponame:Repositorio Institucional EdocUR | spa |
dc.subject | Esclerosis multiple | spa |
dc.subject | Neuromielitis optica | spa |
dc.subject | Vitamina D | spa |
dc.subject | Latitud | spa |
dc.subject | Progresion | spa |
dc.subject | Espectro neuromielitis optica | spa |
dc.subject.ddc | Enfermedades | |
dc.subject.keyword | Multiple sclerosis | eng |
dc.subject.keyword | Neuromyelitis Optica | eng |
dc.subject.keyword | Neuromyelitis Optica Spectrum Disorder | eng |
dc.subject.keyword | vitamin D | eng |
dc.subject.keyword | Latitude | eng |
dc.subject.keyword | progression | eng |
dc.subject.lemb | Esclerosis multiple | spa |
dc.subject.lemb | Neuromielitis Óptica | spa |
dc.subject.lemb | Vitamina D | spa |
dc.title | Prevalencia del déficit de vitamina D y su relación con la expresión clínica de la Esclerosis Múltiple y Neuromielitis óptica en Bogotá | spa |
dc.type | masterThesis | eng |
dc.type.hasVersion | info:eu-repo/semantics/acceptedVersion | |
dc.type.spa | Tesis de maestría | spa |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- Tesis vitamina D y enf. desmielinizantes.pdf
- Tamaño:
- 872.99 KB
- Formato:
- Adobe Portable Document Format
- Descripción: